KLOW vs GLOW: What Adding KPV Changes, and What It Does Not

KLOW and GLOW differ by exactly one ingredient: KLOW is GLOW with the tripeptide KPV added. Both contain GHK-Cu, BPC-157 and TB-500. The comparison reduces to one question: what does KPV bring, and is there evidence it changes anything alongside the other three?

Each blend has its own guide — GLOW and KLOW. This page covers only the difference and the choice between them.

KLOW vs GLOW at a glance

Tiers are the grades on each component's library profile: GHK-Cu is limited human, all of it topical; BPC-157, TB-500 and KPV are insufficient. Neither blend has a grade, because there is nothing about the combination to grade.

What KPV is

KPV is lysine-proline-valine, residues 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). It keeps the parent hormone's anti-inflammatory activity but lacks the part of the sequence needed for meaningful MC1R-driven melanogenesis, which is why it does not cause pigmentation.

Its principal reported action is inhibiting NF-κB signalling, reducing transcription of pro-inflammatory cytokines such as interleukin-6 and TNF-α. It is taken up by the peptide transporters PepT1 and PepT2, which are upregulated in inflamed intestinal epithelium.

The other three are described in terms of repair — matrix remodelling, angiogenesis, cell migration. KPV is described in terms of damping an inflammatory signal. That is the whole case for adding it: a fourth pathway rather than a fourth repair compound.

What KPV's evidence actually covers

KPV's literature is preclinical and narrower than the "anti-inflammatory" label suggests. It is concentrated in rodent models of colitis:

• In mice bred to over-express or lack PepT1, KPV prevented colitis-associated tumour formation in normal mice and had no such effect in mice lacking the transporter — evidence that its action in the gut depends on PepT1 uptake (Viennois 2016).

• In rats with chemically induced colitis, KPV captured in a hydrogel and delivered into the colon helped restore the epithelial barrier (Zhao 2022; Sun 2021).

• In a mouse colitis model, KPV loaded into nanoparticles inside a polysaccharide gel reduced inflammation, with the authors reporting efficacy similar to free KPV at a concentration around 12,000-fold lower (Laroui 2010).

Two features matter for any claim about KLOW. Much of the work depends on a delivery system — a hydrogel or nanocarrier holding KPV at inflamed gut tissue — so the effects belong to that formulation, not to free peptide from a vial. And the delivery is local to the gut. A mechanism that relies on a transporter concentrated in inflamed intestine does not describe KPV injected under the skin alongside three other peptides.

No interventional human trial of KPV is registered or indexed in PubMed. There is no human dose.

What KPV does not add

The shorthand "GLOW for repair, KLOW for repair plus inflammation" implies GLOW has nothing to say about inflammation. That is not quite right.

GHK-Cu, the component the two blends share, has anti-inflammatory preclinical data of its own. In a mouse model of chemically induced colitis it lowered TNF-α, IL-6 and IL-1β, reduced tissue damage and increased tight-junction proteins, through a pathway the authors linked to SIRT1 and STAT3 (Mao 2025). Cell work on GHK-Cu also describes broad shifts in inflammatory and remodelling gene expression (Pickart and Margolina 2018). A systematic review of BPC-157 reported reduced inflammatory cytokines in animal models too (Vasireddi 2025).

So KPV does not bring anti-inflammatory activity to a blend that had none. It adds a second compound with rodent anti-inflammatory data, acting through a different proposed route. Whether that second route adds anything measurable on top of the first has never been tested.

Nor does KPV change three other things:

• Copper. KLOW's colour and copper load come entirely from GHK-Cu, exactly as in GLOW.

• The evidence grade. KPV joins BPC-157 and TB-500 at the insufficient tier; the combination was already unstudied.

• Sport status. KLOW contains the same two prohibited components as GLOW.

The evidence tier of the combination

Neither blend has been studied in humans, animals or cells. Each has no mechanism beyond its parts, and component interactions, relative dosing and the pharmacokinetics of co-administration have not been characterised.

The evidence for either name is therefore the evidence for each component, in the model it was studied in:

Even the one human tier is thin. The randomised GHK-Cu trial usually cited tested a topical skincare regimen after laser resurfacing: blinded assessment found no significant difference in redness, wrinkles or skin quality, though patient satisfaction was higher (Miller 2006). BPC-157's literature is overwhelmingly rodent work on gut, tendon, ligament and wound healing (Józwiak 2025), and the systematic review's single clinical study was retrospective, with no clinical safety data found (Vasireddi 2025).

No study has compared KLOW with GLOW. The question the naming invites — is four better than three? — has no experimental answer.

Labels, ratios and what is actually in the vial

The names are vendor names, not standards. Neither "GLOW" nor "KLOW" defines a fixed composition, and three kinds of ambiguity sit on top of the one-component difference:

• Ratio. The proportion of each component is set by the seller and is not consistent between sellers. Adding a fourth component also changes the share of the other three unless the total mass rises to match.

• Total versus per-component mass. A label may give one figure for the whole vial or one per component. The BPC-157 and TB-500 guide works through why that single ambiguity halves or doubles every calculation.

• What "TB-500" means. Material sold under the name varies in exactly which sequence it contains — usually the seven-residue actin-binding motif LKKTETQ or a short sequence containing it, rather than the 43-residue thymosin beta-4 protein. That applies equally to both blends.

So two vials sold as KLOW by different sellers can differ more than a KLOW and a GLOW from the same seller. The name tells you which components to expect; only per-component masses, backed by a certificate of analysis, tell you how much of each — see the guide to reading a COA.

Choosing between them

There is no evidence-based answer to "which works better", so in a research context the decision is about what you are trying to observe:

• If the question concerns GHK-Cu, BPC-157 and TB-500, KPV is an extra variable, and GLOW is the cleaner of the two.

• If the question concerns KPV, a blend buries it under three other compounds; a separate vial is the only way an observation could be attributed to it.

• If the question concerns any single component, neither blend answers it: with several peptides in one draw, no effect can be assigned to any of them.

Separate vials cost more, but they remove the unanswered question of how peptides fare in solution alongside a copper complex and let each component be varied on its own. Related combinations are graded in the peptide stacks directory.

The vial math, briefly

The arithmetic is the same for either blend: one diluent volume, a separate concentration per component. Confirm first whether the label mass is total or per component, because that changes every number that follows. The BPC-157 + TB-500 blend calculator handles two-component vials, and the peptide calculator handles per-component concentrations for larger blends. Neither turns a concentration into a dose; no human dose exists for any of these components.

What the evidence does not show

• That KLOW does anything GLOW does not. No comparison of the two exists.

• That KPV's gut findings transfer to injection. The work used local delivery, largely from engineered carriers.

• That any component works by injection in humans. None of the four has completed a controlled human efficacy trial by that route.

• That the components stay intact together. No published stability work covers either blend.

• A systematic side-effect profile. Reported irritation, nausea or headache come from uncontrolled reports, not trials.

Frequently asked questions

What is the difference between KLOW and GLOW?

One component. GLOW is GHK-Cu, BPC-157 and TB-500; KLOW is the same three plus KPV, a tripeptide fragment of α-MSH researched for anti-inflammatory signalling in gut models. Ratios and totals vary by seller for both.

Is KLOW better than GLOW?

No study has compared them. KLOW adds a compound with a different proposed mechanism — a hypothesis, not evidence. GHK-Cu, in both, already has preclinical anti-inflammatory data.

What does KPV add to KLOW?

On paper, a second anti-inflammatory route: NF-κB inhibition, with uptake through PepT1 in inflamed gut. The support is rodent colitis research, mostly with KPV held in a hydrogel or nanoparticle — not injected, not in humans, not in a blend.

Why are both KLOW and GLOW blue?

Because of the copper in GHK-Cu, which both contain; KPV has none. Blue shows copper is present, and nothing about potency, purity or the other components.